azelastine has been researched along with Nasal Obstruction in 8 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
Nasal Obstruction: Any hindrance to the passage of air into and out of the nose. The obstruction may be unilateral or bilateral, and may involve any part of the NASAL CAVITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if greater efficacy could be achieved with the intranasal antihistamine azelastine and the intranasal corticosteroid fluticasone propionate used concurrently in the treatment of nasal obstruction of persistent non-allergic rhinitis." | 5.20 | [Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis]. ( Guo, L; Liu, J; Sun, X; Wang, D; Yang, J, 2015) |
| "Rhinitis is a common condition that affects a significant proportion of the general population, as well as a high proportion of athletes." | 2.43 | Nasal obstruction, the airway, and the athlete. ( Craig, TJ; Davies, MJ; Fisher, LH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meltzer, E | 2 |
| Ratner, P | 1 |
| Bachert, C | 2 |
| Carr, W | 2 |
| Berger, W | 1 |
| Canonica, GW | 1 |
| Hadley, J | 1 |
| Lieberman, P | 2 |
| Hampel, FC | 2 |
| Mullol, J | 1 |
| Munzel, U | 2 |
| Price, D | 2 |
| Scadding, G | 1 |
| Virchow, JC | 1 |
| Wahn, U | 1 |
| Murray, R | 1 |
| Bousquet, J | 2 |
| Guo, L | 1 |
| Sun, X | 1 |
| Yang, J | 1 |
| Liu, J | 1 |
| Wang, D | 1 |
| Ratner, PH | 1 |
| Van Bavel, J | 1 |
| Amar, NJ | 1 |
| Daftary, P | 1 |
| Wheeler, W | 1 |
| Sacks, H | 1 |
| Bernstein, J | 1 |
| Fisher, LH | 1 |
| Davies, MJ | 1 |
| Craig, TJ | 1 |
| Yamagiwa, M | 1 |
| Stern, MA | 1 |
| Wade, AG | 1 |
| Ridout, SM | 1 |
| Cambell, LM | 1 |
| Thomas, KE | 1 |
| Ollier, S | 1 |
| Ferguson, H | 1 |
| Davies, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis[NCT00660517] | Phase 3 | 607 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| The Role of the Nose for Physical Capacity[NCT04712799] | Phase 4 | 67 participants (Anticipated) | Interventional | 2021-01-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"change from baseline in the 12 hour instantaneous total nasal symptoms score(iTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period.~The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value." (NCT00660517)
Timeframe: day 1 to day 14
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg | -4.4 |
| Azelastine Hcl 548 Mcg | -3.0 |
| Fluticasone Propionate 200 Mcg | -3.5 |
| Placebo | -1.7 |
change from baseline in the 12 hour reflective total nasal symptoms score(rTNSS) consisting of nasal congestion,runny nose,itchy nose and sneezing scored twice daily( AM and PM) in diary cards for the entire 14 day study period The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value. (NCT00660517)
Timeframe: day 1 to day14
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg | -5.3 |
| Azelastine Hcl 548 Mcg | -3.3 |
| Fluticasone Propionate 200 Mcg | -3.8 |
| Placebo | -2.2 |
Change from Baseline in adult ( greater than 18 years of age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the end of 14 days The measurement scale is 0 to 24. A reduction in symptom severity score is indicated by a negative value. (NCT00660517)
Timeframe: day 1 to day 14
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Azelastine HCl 548 Mcg / Fluticasone Propionate 200 Mcg | -1.6 |
| Azelastine Hcl 548 Mcg | -1.2 |
| Fluticasone Propionate 200 Mcg | -1.4 |
| Placebo | -1.0 |
1 review available for azelastine and Nasal Obstruction
| Article | Year |
|---|---|
Nasal obstruction, the airway, and the athlete.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Nasal Obstruction; Phthalazines; Respiratory System | 2005 |
7 trials available for azelastine and Nasal Obstruction
| Article | Year |
|---|---|
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
Topics: Adult; Androstadienes; Anti-Allergic Agents; Cedrus; Disease Progression; Drug Combinations; Female; | 2013 |
[Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis].
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Drug Therapy, Combination; Histamine H1 Antagon | 2015 |
Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Aged; Allergens; Androstadienes; Cedrus; Ch | 2010 |
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
Topics: Administration, Intranasal; Adult; Androstadienes; Disease Progression; Drug Combinations; Female; F | 2012 |
Acoustic evaluation of the efficacy of medical therapy for allergic nasal obstruction.
Topics: Acoustics; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Ag | 1997 |
Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Budesonide; Double-Blind Method; Drug Tolerance | 1998 |
The effect of intranasal azelastine, Rhinolast, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen.
Topics: Administration, Intranasal; Adult; Allergens; Bronchodilator Agents; Female; Hemodynamics; Histamine | 1992 |